Eli Lilly pursues a vaccine deal worth nearly 40hundred million dollars

![Eli Lilly pursues a vaccine deal worth nearly 40hundred million dollars]/blog-images/gen-24295575-c649-4ece-be1f-af4712bc2b9b.avif)

Eli Lilly plans a vaccine-related deal worth nearly 40hundred million dollars. The deal partners are Curevo and LimmaTech. The company said the deal is part of an expansion of its infectious disease research and development.

The company has not yet disclosed the deal’s overall structure or payment details. It said the collaboration is intended to leverage each company’s vaccine technology. Specific terms and timelines will be disclosed later.

The deal comes as the company moves to expand its research and development capabilities in infectious diseases. The company has been expanding vaccine-related collaborations separately from its existing therapeutics business. The company said this deal is a continuation of that effort.

Eli Lilly’s shares rose slightly on the deal news. Trading took place in the market immediately after the announcement. However, the company separately indicated when it would disclose additional information.

Curevo and LimmaTech are companies with vaccine-related technology. Which indications and clinical stages will be involved will be confirmed through additional company disclosures. The agreement concerns work being carried out at the research and development stage.

The company said it would provide additional disclosures on the details of the agreement and the schedule ahead. From an investor perspective, the detailed terms should be confirmed through the company’s disclosures. The announcement is classified as a concrete move related to Eli Lilly’s expansion of infectious disease research and development.